1) RVO - A Six Month, Phase III, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six Month Open Label Extension) to Assess the Safety and Efficacy of 700ug and 350ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Maculard Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion
Protocol Number: 206207-009


2) DME A three year, phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700ug and 350ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the treatment of patients with diabetic macular edema.
Protocol Number: 206207-011


3) DME - A Phase II, 52 Week, Masked, Multicenter, Randomized, Controlled Trial (With Up to 13 Weeks Additional Follow Up) to Assess the Safety and Efficacy of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME).
Protocol Number: 206207-012


4) VIEW1 - A randomized, double masked, active controlled phase III study of the efficacy, safety and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age related macular degeneration (wet AMD.
Protocol Number: VGFT-OD-0605


5) DME - A Double Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME).
Protocol Number: VGFT-OD-0706


6) A Phase III, Randomized, Double Masked, Parallel-Assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis.
Protocol Number: OPKO ACU301C


7) HOLOGRAM, High resolution/Spectral domain OCT (SD-OCT) monitoring in patients with choroidal neovascularization secondary to age related macular degeneration (AMD) and Ranibizumab (Lucentis) outcomes pilot program.
Protocol Number: CRFB002ACA02


8) MBCU, A phase III, multicenter, randomized, parallel group, placebo controlled, double masked study in patients with diabetes mellitus and clinically significant macular edema not within 100 microns from the center of the macula. There are two treatment groups and the treatment duration is approximately 48 months.
Protocol Number: B7A-MC-MBCU


9) CLEAR, The Canadian LUMIGAN RC early access reporting trial. A 3 month open label non-comparative observational study of Bimatoprost 0.01% (LUMIGAN RC) in the clinical setting.
Protocol Number: CLEAR



10) AZARGA, Comparison of the efficacy of AZARGA versus COSOPT in patients with open angled glaucoma or ocular hypertension.
Protocol Number: AZARGA



11) EOP1013, A Phase 2/3, Randomized, Controlled, Double-Masked, Multicenter, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravtireous Injections of 0.3, 0.03 or 0.003mg Pegaptanib Sodium (Macugen), Given As Often As Every 6 Weeks For 3 Years to Sham Injections In Subjects with Diabetic Macular Edema (DME) Involving The Center Of The Macula.
Protocol Number: EOP1013



12) ANCHOR FVF2587g, A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared with Verteporfin (Visudyne) Photodynamic Therapy in Subjects with Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.
Protocol Number: ANCHOR FVF2587g